Markets:

Overview

News

Currencies

International

Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

143.97 +7.35 (+5.38%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped. ↗

May 20, 2025

The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness.

Via Investor's Business Daily

Topics Bankruptcy Government

How Is The Market Feeling About Moderna? ↗

May 20, 2025

Via Benzinga

What's going on in today's session: S&P500 movers ↗

May 19, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

Stocks Mixed, Treasury Bonds Slip On Moody's US Downgrade: What's Driving Markets Monday? ↗

May 19, 2025

U.S. stocks trimmed early-session losses by midday Monday, as investors showed limited concern after Moody's downgraded U.S. sovereign credit from Aaa to Aa1, effectively stripping the world's largest...

Via Benzinga

Topics Economy

Uncover the latest developments among S&P500 stocks in today's session. ↗

May 19, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗

May 19, 2025

Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.

Via Benzinga

Discover which S&P500 stocks are making waves on Friday. ↗

May 16, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

May 16, 2025

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

Via Chartmill

1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid ↗

May 16, 2025

Via The Motley Fool

MRNA Q1 Earnings Call: Management Focuses on Cost Reductions and Pipeline Progress Amid Revenue Shortfall

May 14, 2025

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2...

Via StockStory

Stay informed with the top movers within the S&P500 index on Wednesday. ↗

May 14, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

May 14, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

May 12, 2025

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...

Via StockStory

Topics Government Stocks World Trade

Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025

May 08, 2025

Via ACCESS Newswire

Top gainers and losers in the S&P500 index during Wednesday's after-hours session. ↗

May 07, 2025

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.

Via Chartmill

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN) ↗

May 07, 2025

Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

May 06, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 06, 2025

Via Benzinga

Which S&P500 stocks are gapping on Tuesday? ↗

May 06, 2025

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.

Via Chartmill

Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks ↗

May 06, 2025

The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.

Via Investor's Business Daily

Topics Government Intellectual Property

3 Cash-Heavy Stocks in the Doghouse

May 05, 2025

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Via StockStory

Topics Economy

What's going on in today's session: S&P500 movers ↗

May 01, 2025

Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 ↗

May 01, 2025

Moderna reaffirms 2025 revenue guidance of $1.5 billion–$2.5 billion, cuts 2027 cost forecast by up to $1.7 billion, and targets 2026 approval for its flu/COVID combo shot.

Via Benzinga

Thursday's session: gap up and gap down stock in the S&P500 index ↗

May 01, 2025

Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Moderna Reports Q1 Revenue Drop, Warns Of Delay In Covid/Flu Vaccine Approval: Retail Sentiment Sours ↗

May 01, 2025

The company reported first-quarter revenue of $108 million, down from $167 million in the corresponding period of 2024, and below an analyst estimate of $115.32 million, as per FinChat data.

Via Stocktwits

These S&P500 stocks are moving in today's pre-market session ↗

May 01, 2025

Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session.

Via Chartmill

Moderna (NASDAQ:MRNA) Misses Q1 Revenue Estimates

May 01, 2025

Via StockStory

Moderna Misses Sales Forecasts, But Maintains Full-Year Outlook ↗

May 01, 2025

The company is well known for its Covid vaccine. But sales came in below expectations.

Via Investor's Business Daily

Topics Earnings Government

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates

May 01, 2025

Via ACCESS Newswire

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.